Are you Dr. Meyer?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 32 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3601 S 6th Ave
Tucson, AZ 85723Phone+1 520-629-4629Fax+1 520-629-1756- Is this information wrong?
Summary
- Dr. Paul Meyer, MD is a board certified pathologist in Tucson, Arizona. He is currently licensed to practice medicine in Arizona, Nevada, and Montana. He is affiliated with Tucson VA Medical Center.
Education & Training
University of Nebraska Medical Center College of MedicineFellowship, Hematopathology, 2008 - 2010
Loyola University Medical CenterResidency, Pathology-Anatomic and Clinical, 2004 - 2008
Pennsylvania State University College of MedicineClass of 2004
Certifications & Licensure
AZ State Medical License 2012 - Present
CA State Medical License 2011 - Present
NE State Medical License 2007 - 2024
NV State Medical License 2011 - 2013
WA State Medical License Active through 2013
MT State Medical License 2011 - 2013
ID State Medical License 2010 - 2012- American Board of Pathology Pathology - Anatomic/Pathology - Clinical
- American Board of Pathology Hematopathology
- Join now to see all
Publications & Presentations
PubMed
- 14 citationsIsolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome.Gabriel C. Caponetti, Bhavana J. Dave, Anamarija M. Perry, Lynette M. Smith, Smrati Jain, Paul N. Meyer, Martin Bast, Philip J. Bierman, Robert G. Bociek, Julie M. Vos...> ;Leukemia & Lymphoma. 2015 Apr 1
- 11 citationsThe great masquerader of malignancy: chronic intestinal pseudo-obstructionJosephine A. Taverna, Hani M. Babiker, Seongseok Yun, Maria C. Bishop, Sarah Lau-Braunhut, Paul N. Meyer, Thomas Enzler> ;Biomarker Research. 2014 Dec 5
- 697 citationsConcurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and PrednisoneNathalie A. Johnson, Graham W. Slack, Kerry J. Savage, Joseph M. Connors, Susana Ben-Neriah, Sanja Rogic, David W. Scott, King Tan, Christian Steidl, Laurie H. Sehn, W...> ;Journal of Clinical Oncology. 2012 Oct 1
- Join now to see all
Press Mentions
Sirolimus (Rapamycin) for the Targeted Treatment of the Fibrotic Sequelae of Graves’ OrbitopathyFebruary 14th, 2019
Hospital Affiliations
Tucson VA Medical CenterTucson, Arizona
